Humana plans to leave COO role vacant after James Murray retires

John Gregory | | Health Exec | Management

Humana executive vice president and COO James Murray will step down from his post on March 31.

The announcement was made as part of the insurer’s fourth quarter financial results for 2016. Murray has been with Humana since 1989, being promoted to COO role in 2006 after serving in a similar capacity for different business segments, as well as holding titles like CFO and vice president of finance.

“Jim’s commitment to Humana and contributions to our success are without parallel,” said Humana President and CEO Bruce Broussard. “Since joining the organization in 1989, his passion for growing our company while serving our customers has been evident to all who have worked with him and learned from him. I wish him well in his next endeavors, and am pleased that the company will continue to benefit from his advice and experience through the end of the year.”

After retiring, Murray will stay on as an advisor until the end of the year. He won’t have a successor, as Humana said it “does not anticipate filling” the COO position at this time. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

OCR investigating Michigan health system over possible violation of 'Church Amendments'
Veterans Affairs denies it discriminates based on politics, marital status
Ivenix infusion kits recalled by FDA due to serious manufacturing defect
FDA recalls pediatric breathing kits after eight serious injuries
Dental marketing firm Gargle likely source of 8M leaked patient records
FDA recalls Zyno infusion pumps, citing risk of death

Around the web

Cardiovascular Business
AMA agrees to help after initial request for an independent cardiovascular board was denied

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

Cardiovascular Business
Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

Cardiovascular Business
AMA House of Delegates helps cardiology groups influence healthcare policies

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.